134
Views
11
CrossRef citations to date
0
Altmetric
Original Articles

In silico assessment of potential leads identified from Bauhinia rufescens Lam. as α-glucosidase and α-amylase inhibitors

, , , , , & show all
Pages 159-169 | Received 20 Mar 2020, Accepted 14 Jul 2020, Published online: 27 Jul 2020
 

Abstract

Introduction

Natural products play a pivotal role in innovative drug discovery by providing structural leads for the development of new therapeutic agents against various diseases.The present study aims to focus on the in silico assessment of the therapeutic potential of antidiabetic phytoconstituents which were identified and isolated from the extracts of Bauhinia rufescens Lam, a medicinal plant traditionally used for various pharmacotherapeutic purposes.

Method

The physicochemical and pharmacokinetic parameters of the previously isolated thirty eight compounds were predicted using SwissADME web tool whereas OSIRIS Property Explorer was used for toxicity risk assessment and drug- likeliness. Twelve compounds were selected for docking on human α-glucosidase and α-amylaseenzymes using Autodock 4.0 software. Furthermore, the active extract was in vivo tested for the antidiabetic activity and then identified usingTLC bioautographic method.

Results and Discussion

Eriodictyol was found to have the highest potential as an inhibitor against α-amylase with binding energy of −9.92 kcal/mol. Rutin was the most potent against α-glucosidase with binding energy of-9.15 kcal/mol. A considerable number of hydrogen bonds and hydrophobic interactions were computed between the compounds and the enzymes thereby making them energetically favorable and suggesting inhibition of these two enzymes as a plausible molecular mechanism for their antidiabetic effect.

Conclusion

These two flavonoids could therefore be used as potential leads for structure- based design of new effective hypoglycemic agents.

Acknowledgements

Authors extend their appreciation to Researchers Supporting Project number (RSP-2020/119), King Saud University, Riyadh, Saudi Arabia for funding. Authors are also thankful for Faculty of Pharmacy, University of Khartoum and College of Pharmacy, King Saud University for technical support.

Author contributions

Wadah conducted the extraction, isolation, wrote the discussion and revise the manuscript, Esraa perform the pharmacokinetic analysis and write its method and results, Shaza and Mona performed the in silico molecular docking, Shaza wrote the manuscript draft, Hassan, Abelkaleg and Ramzi revise and edit.

Disclosure statement

Authors declare no conflict of interest.

Data availability statement

All dataset supporting this article is available within the article and its supplementary files.

Additional information

Funding

The study was funded by Researchers Supporting Project number [RSP-2020/119], King Saud University, Riyadh, Saudi Arabia.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.